New York-based psychedelic biotechnology company Gilgamesh Pharmaceuticals has received a grant of USD 14 million from the National Institute on Drug Abuse.
The new funds will be allocated to conducting IND-enabling toxicology studies, GMP manufacturing, and Phase 1/1b clinical trials for GM-3009, an ibogaine analog for treating substance use disorders.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.